Spots Global Cancer Trial Database for Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
Official Title: Patient-Reported AutoImmunity Secondary to Cancer immunothErapy
Study ID: NCT03849131
Conditions
Interventions
Study Description
Brief Summary: This is a real life observational longitudinal study aiming to identify autoimmune manifestations in patients treated with "checkpoint inhibitors" in mono or combo therapy in real life. The study is based on patients reported experience validated by physician, recruited in cancer centers in France with another data collection from a French healthcare data claims database and a biological collection.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hopitaux universitaires de strasbourg, Strasbourg, Alsace, France
Contact Details
Name: Jacques-Eric GOTTENBERG, MD, PhD
Affiliation: University Hospital, Strasbourg, France
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
